{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=10", "query": { "intervention": "Peptide vaccine", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 749, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:24:30.084Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00423254", "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian", "Melanoma", "Renal", "Prostate", "Colorectal", "Endometrial Carcinoma", "Cervical Carcinoma", "Testicular Cancer", "Thyroid Cancer", "Small Cell Lung Carcinoma", "Mesothelioma", "Breast Carcinoma", "Esophageal Carcinoma", "Gastric Cancer", "Pancreatic Carcinoma", "Neuroendocrine Cancer", "Liver Cancer", "Gallbladder Cancer", "Biliary Tract Cancer", "Anal Carcinoma", "Bone Sarcomas", "Soft Tissue Sarcomas", "Carcinoma of Unknown Origin, Primary" ], "interventions": [ { "name": "PSMA/PRAME", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-02", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 5, "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sparks", "state": "Nevada" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423254" }, { "nct_id": "NCT02065973", "title": "An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-risk HPV Infection and Biopsy-proven CIN1" ], "interventions": [ { "name": "R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PDS Biotechnology Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 12, "start_date": "2014-02", "completion_date": "2015-12-30", "has_results": false, "last_update_posted_date": "2018-12-13", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 2, "location_summary": "Port Jefferson, New York • The Bronx, New York", "locations": [ { "city": "Port Jefferson", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065973" }, { "nct_id": "NCT00019682", "title": "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 Antigen", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "1999-12", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Riverside, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019682" }, { "nct_id": "NCT00626015", "title": "Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasms of Brain" ], "interventions": [ { "name": "PEP-3-KLH conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "daclizumab", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "PEP-3-KLH", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "John Sampson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2007-03", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2016-01-21", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00626015" }, { "nct_id": "NCT00334776", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100:209-217(210M) peptide vaccine", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 6, "start_date": "2003-10", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 2, "location_summary": "Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00334776" }, { "nct_id": "NCT06742281", "title": "A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "CVXGA (CVXGA50)", "type": "BIOLOGICAL" }, { "name": "COMIRNATY®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CyanVac LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 432, "start_date": "2024-12-05", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 55, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742281" }, { "nct_id": "NCT00892567", "title": "Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "9 Peptides from Her-2/neu, CEA, & CTA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2009-05", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892567" }, { "nct_id": "NCT02019524", "title": "Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "E39 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "E39 vaccine then J65 vaccine", "type": "BIOLOGICAL" }, { "name": "J65 vaccine then E39 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "COL George Peoples, MD, FACS", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2013-09-30", "completion_date": "2016-12-06", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019524" }, { "nct_id": "NCT00688090", "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Melanoma", "Stage III and IV Melanoma" ], "interventions": [ { "name": "Biological: MKC1106-MT", "type": "BIOLOGICAL" }, { "name": "Biological: MKCC1106-MT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 2, "location_summary": "Los Angeles, California • Tampa, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688090" }, { "nct_id": "NCT06691035", "title": "Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Metastatic Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" }, { "name": "DC1 native/mutated ESR1", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-11-04", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-14T09:24:30.084Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06691035" } ] }